Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Immune regulation of NF-kappaB in Dendritic Cell subsets by the ubiquitin editing enzyme A20 (A20 DC SUBSETS)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Life-long training and career development
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Netherlands
Call:  (FP7-PEOPLE-2011-CIG, 2011)
Start date: 2012-03-01
End date: 2016-02-29
Duration (months): 48.0
Total project cost (EUR): 100000.0
EU funding (EUR): 100000.0
Participants: 1
Project status: CLOSED

Dendritic cells (DCs) are strategically positioned as sentinels that process antigens and present these to other immune cells, thereby acting as crucial messengers between innate and adaptive immunity. DCs are activated by various receptors, including Toll-like receptors (TLRs) that recognize microbial products. TLR stimulation leads to activation of the transcription factor NF-κB, which is the key regulator of pro-inflammatory genes. NF-κB activation is tightly regulated by ubiquitination, a modification process that targets proteins for proteasomal degradation. The most important negative regulator of NF-κB activation is the ubiquitin-modifying enzyme A20/Tnfaip3. We have recently established an in vivo constitutive NF-κB activation mouse model system by DC-specific A20 gene ablation (using the Cre/loxP system). Our preliminary results demonstrate that A20 in DCs critically controls inflammation in the context of allergy and autoimmunity. Consistent with defective termination of TLR/NF-κB signalling, we found that A20KO DCs manifest an activated phenotype and DC-A20KO mice exhibit increased inflammation and high levels of serum autoantibodies. Remarkably however, DC-A20KO mice are protected from allergic asthma and experimental autoimmune encephalomyelitis. The proposal will provide fundamental knowledge on the effects of NF-κB activation in different DC subsets and should offer a starting point for therapies for inflammatory diseases based on ubiquitin modification.

Keywords: inflammatory disease,immunity,activation,regulation,dendritic cell subsets,t cell differentiation,nf-kappa b,ubiquitination,a20/tnfaip3
In Vitro Derivation of Beta Cells by Ectopic Expression of Pancreatic Transcription Factors (TRANSBETA)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Life-long training and career development
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Portugal
Call:  (FP7-PEOPLE-2011-CIG, 2011)
Start date: 2012-06-01
End date: 2016-05-31
Duration (months): 48.0
Total project cost (EUR): 100000.0
EU funding (EUR): 100000.0
Participants: 1
Project status: CLOSED

Type 1 diabetes mellitus affects an estimated 0,5% of the world population. Autoimmune rejection results in destruction of the insulin producing beta cells of the pancreas, leading to both acute and long term complications. Daily injection of exogenous insulin allows long term managment of the condition, but does not avoid long term complications. Reconstitution of the beta cell compartment by pancreas or cadaveric islet transplantation is heavily restricted by shortage of donor material and immune rejection issues. Any progress in obtaining large number of transplantable insulin producing cells would be a major advance towards a cure for the disease. The general objective of this proposal is to establish a method to transdifferentiate adult human cells to the beta cell phenotype by direct reprogramming by forced expression of an optimized set of pancreas specific transcription factors. The underlying experimental rationale is that sequential or combinatorial ectopic expression of transcription factors can induce recipient cells to establish a beta cell regulatory state. The experimental methodology is to clone a set of native or modified transcription factors known to be involved in pancreatic development into viral vectors and use them to transdiferentiate adult human cell types in conditions known to favor beta cell differentiation.

Keywords: diabetes,transdifferentiation,beta cells,insulin,pancratic islet,transcription factors,health sciences
Mechanics of HIV Reverse Transcriptase (HIV RT)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Life-long training and career development
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Netherlands
Call:  (FP7-PEOPLE-2011-CIG, 2011)
Start date: 2012-02-01
End date: 2016-01-31
Duration (months): 48.0
Total project cost (EUR): 100000.0
EU funding (EUR): 100000.0
Participants: 1
Project status: CLOSED

The oncogenic human immunodeficiency virus (HIV) currently infects an estimated 33 million individuals and has claimed more than 25 million lives. The primary treatment of HIV consists of a cocktail of several classes of antiretroviral drugs targeting various components of the HIV virus. The most utilized target of antiretroviral drugs is reverse transcriptase (RT), an enzyme that transforms the viral genome from ssRNA to dsDNA. Unfortunately, significant gaps remain in our understanding of how RT functions. Using single molecule techniques, I have previously shown that the orientation of RT while associated with nucleic acids is highly dynamic and characterized by both flipping and sliding transitions. These transitions are associated with processing of the poly-purine tract (PPT) sequence, the rapid targeting of RT to the ends of long regions of double stranded nucleic acids, and strand displacement synthesis. In this grant, I propose to develop additional single molecule assays to further study the dynamic interactions of RT with physiologically relevant nucleic acid substrates. These new assays will allow my lab to address specific questions relevant to the understanding of this key enzyme. First, we will determine the mechanisms of the flipping and sliding transitions and test whether these transitions are required for the successful completion of key steps in the reverse transcription reaction. Second, we will probe the detailed mechanism of strand displacement synthesis and determine the energetic contacts RT uses to stabilize the annealed primer strand. Finally, we will also measure the effects of antiretroviral drugs in preventing the completion of individual steps of the reverse transcription process to identify potentially novel mechanisms of inhibition. Taken together, this research offer fundamental insights into protein and nucleic acid interactions and help to define the next generation of anti-HIV drugs.

Keywords: physical sciences,health sciences
Novel Methods in Computational Finance (STRIKE)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Initial Training Networks
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Germany,Slovakia,Spain,Bulgaria,Portugal,Germany,Austria,Netherlands,United Kingdom,Germany,Belgium
Call:  (FP7-PEOPLE-2012-ITN, 2012)
Start date: 2013-01-01
End date: 2016-12-31
Duration (months): 48.0
Total project cost (EUR): 3582470.98
EU funding (EUR): 3582470.98
Participants: 11
Project status: CLOSED

In recent years the computational complexity of mathematical models employed in financial mathematics has witnessed a tremendous growth. Advanced numerical techniques are imperative for the most present-day applications in financial industry. The motivation for this training network is the need for a network of highly educated European scientists in the field of financial mathematics and computational science, so as to exchange and discuss current insights and ideas, and to lay groundwork for future collaborations. Besides a series of internationally recognized researchers from academics, leading quantitative analysts from the financial industry also participate in this network. The challenge lies in the necessity of combining complementary techniques and skills such as mathematical analysis, sophisticated numerical methods and stochastic simulation methods with deep qualitative and quantitative understanding of mathematical models arising from financial markets. The main training objective is to prepare, at the highest possible level, young researchers with a broad scope of scientific knowledge and to teach transferable skills, like social awareness which is very important in view of the recent financial crises. The current topic in this network is that the financial crisis in the European countries is a contagion and herding effect and is clearly outside of the domain of validity of Black-Scholes and Merton's theory, since the market is not Gaussian and it is not frictionless and complete. In this research training network our aim is to deeper understand complex (mostly nonlinear) financial models and to develop effective and robust numerical schemes for solving linear and nonlinear problems arising from the mathematical theory of pricing financial derivatives and related financial products. This aim will be accomplished by means of financial modelling, mathematical analysis and numerical simulations, optimal control techniques and validation of models.

Keywords: m117,nonlinear black-scholes,hybrid monte-carlo,splitting methods,kinetic financial models,contagion effects,optimal control,sabr stochastic volatility,gpu programming,model order reduction,e104
Micro Retina Thermal Infrared (MIRTIC)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Electronic Numerical Integrator and Computer
Action type: Collaborative project
Partnership: ENIAC (Art-185)
Countries involved: France,France,Greece,France,Germany
Call:  (ENIAC-2011-2, 2011)
Start date: 2012-02-01
End date: 2016-01-01
Duration (months): 47.0
Total project cost (EUR): 24791515.0
EU funding (EUR): 4140183.0
Participants: 5
Project status: CLOSED

The MIRTIC project goal is to respond to market expectation by developing and providing a new type of affordable low resolution IR sensor. This new line of IR sensors is designed to fill an unmet need in applications seeking to achieve maximum system efficiency in the everyday use of energy. The market trend is oriented on replacement of available single element IR sensor by a small 2 D array which enables an “understanding” of the scene by delivering not only temperature indication but also spatial information. This last information will improve efficiency of management system in charge of air cooling (HVAC), automatic lighting, security (access control, people counting), and health care (IR endoscopy). The project is divided in technology development part and application development part which are running in parallel. ? Technological part: CEA/LETI will mainly develop an innovative vacuum Pixel Level Packaging technology which will give key advantage over the competitors for cost reduction. ULIS will be in charge of infrared algorithm development to integrate them on sensor chip as well as sensor architecture development in order to be able to suppress the shutter which is still used in uncooled IR imaging detector systems. ISD will develop electronics boards to operate the sensor. ? Application part: application partners will be able to develop and test systems in order to react on sensor definition. This step involved ISD (Greece) for image synchronization development which can enable the use of multi-sensor heads in a same area without information overlapping, METAIO for enhanced reality management systems and Schneider Electric for home automation. Surveillance application with visible and infrared fusion could also be addressed by this development. As a result of this project, a new product line will be created for low cost sensor production and a set of new applications will be validated by partners.

Keywords: low resolution ir sensor,home automation,augmented reality,image synchronization
European E&M 450mm Pilotline Readiness (EEM450PR)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Electronic Numerical Integrator and Computer
Action type: Collaborative project
Partnership: ENIAC (Art-185)
Countries involved: Netherlands,Israel,United Kingdom,Austria,Germany,Germany,Germany,Belgium,Austria,Netherlands,Netherlands,United Kingdom,France,Germany,Switzerland,Netherlands,Germany,Germany,Ireland,Germany,Germany
Call:  (ENIAC-2011-2, 2011)
Start date: 2012-04-01
End date: 2015-03-01
Duration (months): 35.0
Total project cost (EUR): 84120124.0
EU funding (EUR): 14048060.0
Participants: 32
Project status: CLOSED

Aim of the EEM450PR project is to continue the engagement of the European semiconductor equipment and materials industry in the 450mm wafer size transition that started with the ENIAC JU EEMI450 initiative. It will also bring about the start of a vision to place an equipment development pilot line in the imec facility in Leuven. This will provide Europe with a complementary activity for 450mm equipment, and later on sub 10nm process development. The consortium comprises 34 members (from 10 different European countries); 11 are SMEs and 4 are research institutes. The main objective of the work on lithography is the proof of concept at test bench level of 450 mm critical wafer stage technology to get prepared for 450 mm early lithography prototype realization in a subsequent phase. The work on materials is the follow-up activity of the EEMI450 project to reach the next level of 450mm wafer quality. To be able to produce these wafers with the required capabilities new sophisticated equipment for the Chemical Mechanical Polishing process step as well as very advanced equipment for final cleaning procedures will be developed and will be integrated in a 450mm wafer line. Next to technology development also a 450mm equipment development pilot line facility will be prepared by developing state-of-the-art facilities readiness, including stringent energy and contamination considerations taking recent ISMI Guidelines, Semi Standards and ITRS requirements and activities into account. Furthermore, work will be done on the development of pilotline-ready equipment and modules, and further optimization of prototypes, concerning front-end (wafer based) semiconductor processing. The companies that were involved in the ENIAC EEMI450 project will use the results obtained therein for further development of their respective equipment. Finally, metrology equipment performance will be enhanced to improve the current 300mm cost of ownership for 12nm technology control on 450mm wafers.

Keywords: technology development on equipment and materials to enable pilot readiness for 450mm wafer introduction
Bile acids targeting Retinoic Related Orphan Receptor gamma for the Treatment of Obesity associated Insulin Resistance and Type 2 Diabetes (DIBAROR)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Proof of concept grants
Action type: Support for frontier research (ERC)
Countries involved: Switzerland
Call:  (ERC-2011-PoC, 2011)
Start date: 2012-04-01
End date: 2013-03-31
Duration (months): 12.0
Total project cost (EUR): 159065.4
EU funding (EUR): 145697.0
Participants: 1
Project status: CLOSED

Within the past three years as part of the ERC funding, we have performed extensive research to identify novel factors that might influence adipogenesis and thus control development of obesity and associated metabolic disorders. One of the factors we identified in a translational approach, was the transcription factor retinoic acid orphan receptor gamma (RORγ) which regulates fat cell formation in mice and humans. RORγ is considered as an orphan nuclear receptor as only weak natural ligands that antagonize receptor function have been identified so far. We were able to identify a high affinity natural occurring ligand (Ba1) which is a bile acid isoform and which potently represses the activity of RORγ. Genetic ablation of RORγ expression can rescue obesity associated development of type 2 diabetes, similarly in mice Ba1 supplementation of the diet, prevents the development of diet induced type 2 diabetes. Thus, Ba1 is a ligand for RORγ that has the potential to serve as a therapeutic agent for the treatment of obesity associated insulin resistance and type 2 diabetes. With this application we would add value to the current state of the project in different aspects. We plan to perform a toxicological assessment of Ba1 which will show if it can enter further development without problems. In parallel a set of well-defined Ba1 analogs will be synthesized with the aim to widen our IP position. Furthermore, we plan a detailed evaluation of the in vitro and in vivo efficacy of the newly synthesized Ba1 analogues. We anticipate that it will be possible to implement this naturally occurring bile acid in the context of two separate therapies. Ba1 can be envisioned to be employed as a nutraceutical in common foods. Also, Ba1 could find a niche in the ever-expanding over-the-counter market. Ba1 or modified derivatives may also be useful as stand-alone medication, to treat metabolic co-morbidities such as type 2 diabetes associated with obesity.

Keywords: 205641
EDCTP-Plus: Laying the foundations for the EDCTP-II programme (EDCTP-PLUS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Health
Action type: Coordination and support actions
Countries involved: Netherlands
Call:  (FP7-Adhoc-2007-13, 2007)
Start date: 2012-01-01
End date: 2014-12-31
Duration (months): 36.0
Total project cost (EUR): 7734128.0
EU funding (EUR): 7734128.0
Participants: 1
Project status: CLOSED

Background: The European and Developing Countries Clinical Trials Partnership (EDCTP) was established by the European Union in 2003 in response to the global health crisis caused by the major three poverty-related diseases (PRDs) HIV/AIDS, tuberculosis and malaria and as the first initiative based on Article 185 (ex-Art. 169) of the Treaty on the Functioning of the European Union (TFEU) aimed at EU financial support for programmes undertaken by several EU Member States. Aim: The coordination and support action, EDCTP-Plus, refers to a programme of activities to be carried out during the period 2012-2014 in preparation for the anticipated second phase of EDCTP (EDCTP-II) which will be funded through Horizon2020 and thus not start before January 2014. Methods: Activities will be undertaken to establish a strong and reliable foundation for a second phase of the EDCTP Programme, which is expected to have an expanded EU mandate and budgetary support. The objectives of the project are: • To develop integration and funding strategies through the mapping of and cooperation between national programmes and research activities to address the major poverty-related and neglected infectious diseases • To enhance future cooperation and synergy with industry, like-minded organisations, non-EDCTP partner countries and other funding agencies and stakeholders working on poverty-related and neglected infectious diseases • To strengthen the capacity development, coordination and networking activities undertaken by the current EDCTP programme in coordination with other organisations • To increase awareness and profile of EDCTP, its achievements and impact, including through a high-level conference in Brussels involving political representation by all parties with an interest in EDCTP • To improve and update EDCTP's strategic and operational implementation processes and systems in view of the expected expansion of remit with EDCTP-II • To develop a robust evaluation framework for monitoring and evaluation of the impact of EDCTP- II. Impact: The expected impact will be a maintained profile of the EU-Africa research partnership and a strengthened foundation to underpin and implement the EDCTP-II programme with an expanded scope and budget.

Keywords: health,hiv/aids,tuberculosis,malaria,clinical research,joint programming,ethics,capacity-building,sub-saharan africa,phase ii trials,phase iii trials,article 185,treatment,diagnostics
Prolonged inhibition of semaphorine3a pathway via a bio-degradable implant towards a better therapy for visual sensory impairments (VISION)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Israel,Germany,Spain,Spain
Call:  (FP7-HEALTH-2012-INNOVATION-2, 2012)
Start date: 2012-09-01
End date: 2016-08-31
Duration (months): 48.0
Total project cost (EUR): 7413800.0
EU funding (EUR): 5661253.0
Participants: 5
Project status: CLOSED

The visual pathway is a component of the central nervous system (CNS) and therefore is not regenerative. Acute optic nerve injury, ischemic optic neuropathy and glaucoma are conditions that initially lead to partial blindness and eventually could lead to total blindness. Extensive neuron and retinal ganglion cells (RGC) death is evidenced in these pathologies. Semaphorin 3A (Sema3A) is a cell secreted protein that participates in the axonal guidance pathways. Partner TAU was the first to show that Sema-3A is also capable of inducing neuronal cell death. Elevated levels of Sema3A were than found in glaucoma. TAU further showed the viscous role of Sema3a that is mediating the vast RCG apoptosis following optic nerve injury. Importantly, marked inhibition of RGC loss was achieved when axotomized eyes were co-treated by intravitreous injection of antibodies against the Sema3A providing the proof of concept for the therapeutic approach to inhibit the Sema3A pathway following optic nerve injury. This concept was recently validated by partner SIC who developed a small molecule weight inhibitor of Sema3A and showed that this inhibitor promotes neural regeneration of damaged axons. Acute or chronic assault to neural cells create an immediate death of part of the population and a signal for further death of the remaining cells close to the damaged area. The project goal is to develop a therapeutic approach to stop further death of neural cells by providing prolonged inhibition of the apopototic pathway of Sema-3A using antibody targeted to this protein or a low MW inhibitor of sema3A. The Sema3A inhibitors would be constantly released from a novel intraocular biodegradable implant. The clinical efficacy of this approach will be evaluated in two common devastating pathologies: optic nerve injury and glaucoma.

Keywords: semaphorine 3a,implant,regeneration,glaucoma,optic nerve,nanoparticles